TNF and Sepsis: Regarding anti-TNF-α therapy for patients with sepsis a recent meta-analysis (54) included seventeen studies with a total of 8,971 patients and when all forms of anti-TNF-α therapy were pooled together, there was a significant reduction of 28-day all-cause mortality with respect to placebo and individually the subgroup analysis showed that anti-TNF-α antibodies (monoclonal and polyclonal) reduced mortality (OR = 0.90, 95% CI: 0.81–0.99; p = 0.04).